The anti-CTLA-4 monoclonal antibody ipilimumab was the first checkpoint inhibitor (CPI) to receive Food and Drug Administration approval for the treatment of metastatic malignant melanoma. The gene discussed is CTLA4; the disease is metastatic melanoma.